ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebocontrolled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

Professor Simon Hart S.Hart@hull.ac.uk
Professor in Respiratory Medicine

Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease Jun 30, 2017 - Aug 31, 2020
An in silico computational model of sarcoidosis

BREATHE: Breathlessness RElief AT HomE Apr 1, 2019 - Oct 31, 2021
A feasibility study to address this RQ:
Does a paramedic-administered short non-pharmacological complex breathlessness intervention improve breathlessness and reduce conveyance to ED for people with breathlessness crisis compared with usual pr... Read More about BREATHE: Breathlessness RElief AT HomE.

Sir Jules Thorn PhD Scholarship Programme 2016 Sep 1, 2016 - Aug 31, 2019
Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lungs that affects about 15,000 people in the UK. There is no curative treatment and 5-year survival in IPF is worse than many cancers. Despite this, the pathogenesis of IPF... Read More about Sir Jules Thorn PhD Scholarship Programme 2016.

Characterisation of monocyte CD200R in pulmonary sarcoidosis Mar 1, 2016 - Feb 28, 2018

A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis Mar 1, 2019 - Sep 30, 2020
Patients with sarcoidosis need treatment options that improve their disease without causing unacceptable side effects. Currently, steroids tablets are offered for severe sarcoidosis, but side effects can be dangerous and personally distressing, and s... Read More about A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis.